CK Life Sciences Int'l. (Holdings) Management
Management criteria checks 3/4
CK Life Sciences Int'l. (Holdings)'s CEO is Alan Abel Yu, appointed in Sep 2020, has a tenure of 3.58 years. total yearly compensation is HK$14.79M, comprised of 74.1% salary and 25.9% bonuses, including company stock and options. directly owns 0.023% of the company’s shares, worth HK$776.23K. The average tenure of the management team and the board of directors is 13.6 years and 9.1 years respectively.
Key information
Alan Abel Yu
Chief executive officer
HK$14.8m
Total compensation
| CEO salary percentage | 74.1% |
| CEO tenure | 3.6yrs |
| CEO ownership | 0.02% |
| Management average tenure | 13.6yrs |
| Board average tenure | 9.1yrs |
Recent management updates
Recent updates
CK Life Sciences Int'l. (Holdings) (HKG:775) Use Of Debt Could Be Considered Risky
Mar 26
Here's Why CK Life Sciences Int'l. (Holdings) (HKG:775) Can Manage Its Debt Responsibly
Sep 27Does CK Life Sciences Int'l. (Holdings) (HKG:775) Have A Healthy Balance Sheet?
Sep 16Estimating The Intrinsic Value Of CK Life Sciences Int'l., (Holdings) Inc. (HKG:775)
Aug 21These 4 Measures Indicate That CK Life Sciences Int'l. (Holdings) (HKG:775) Is Using Debt Extensively
Apr 14CK Life Sciences Int'l., (Holdings) Inc. (HKG:775) Delivered A Weaker ROE Than Its Industry
Mar 18If You Had Bought CK Life Sciences Int'l. (Holdings) (HKG:775) Shares Five Years Ago You'd Have Earned 45% Returns
Feb 01
What Kind Of Shareholders Hold The Majority In CK Life Sciences Int'l., (Holdings) Inc.'s (HKG:775) Shares?
Jan 04CK Life Sciences Int'l. (Holdings) (HKG:775) Has A Somewhat Strained Balance Sheet
Dec 09We Wouldn't Rely On CK Life Sciences Int'l. (Holdings)'s (HKG:775) Statutory Earnings As A Guide
Nov 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | HK$15m | HK$11m | HK$17m |
| Sep 30 2023 | n/a | n/a | HK$61m |
| Jun 30 2023 | n/a | n/a | HK$104m |
| Mar 31 2023 | n/a | n/a | HK$118m |
| Dec 31 2022 | HK$14m | HK$11m | HK$132m |
| Sep 30 2022 | n/a | n/a | HK$130m |
| Jun 30 2022 | n/a | n/a | HK$128m |
| Mar 31 2022 | n/a | n/a | HK$145m |
| Dec 31 2021 | HK$14m | HK$10m | HK$163m |
| Sep 30 2021 | n/a | n/a | HK$150m |
| Jun 30 2021 | n/a | n/a | HK$138m |
| Mar 31 2021 | n/a | n/a | HK$132m |
| Dec 31 2020 | HK$14m | HK$11m | HK$125m |
| Sep 30 2020 | n/a | n/a | HK$112m |
| Jun 30 2020 | n/a | n/a | HK$98m |
| Mar 31 2020 | n/a | n/a | HK$140m |
| Dec 31 2019 | HK$14m | HK$10m | HK$182m |
| Sep 30 2019 | n/a | n/a | HK$223m |
| Jun 30 2019 | n/a | n/a | HK$263m |
| Mar 31 2019 | n/a | n/a | HK$263m |
| Dec 31 2018 | HK$13m | HK$10m | HK$263m |
| Sep 30 2018 | n/a | n/a | HK$261m |
| Jun 30 2018 | n/a | n/a | HK$259m |
| Mar 31 2018 | n/a | n/a | HK$259m |
| Dec 31 2017 | HK$12m | HK$9m | HK$258m |
Compensation vs Market: Alan Abel's total compensation ($USD1.89M) is above average for companies of similar size in the Hong Kong market ($USD404.47K).
Compensation vs Earnings: Alan Abel's compensation has been consistent with company performance over the past year.
CEO
Alan Abel Yu (67 yo)
3.6yrs
Tenure
HK$14,788,000
Compensation
Mr. Ying Choi Yu, also known as Alan Abel, has been the Chief Executive Officer at CK Life Sciences Int'l., (Holdings) Inc. since September 1, 2020 and serves as its Vice President and Executive Director....
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 22yrs | HK$125.00k | 0.023% HK$ 776.2k | |
| CEO, VP & Executive Director | 3.6yrs | HK$14.79m | 0.023% HK$ 776.2k | |
| President & Executive Director | 21.8yrs | HK$2.58m | 0.065% HK$ 2.1m | |
| Senior VP | no data | HK$1.60m | 0.023% HK$ 776.2k | |
| VP, Chief Scientific Officer & Executive Director | 5.4yrs | HK$6.13m | no data | |
| Chief Financial Officer | no data | no data | no data | |
| Chief Operating Officer of Global Operations | no data | no data | no data | |
| Chief Manager of Human Resources & Administration | no data | no data | no data | |
| Legal Counsel | no data | no data | no data | |
| Chief Corporate Affairs Officer | no data | no data | no data | |
| Company Secretary | 22.3yrs | no data | no data | |
| Chief Executive Officer of Regenal Investments Pty Limited | no data | no data | no data |
13.6yrs
Average Tenure
62yo
Average Age
Experienced Management: 775's management team is seasoned and experienced (13.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 22yrs | HK$125.00k | 0.023% HK$ 776.2k | |
| CEO, VP & Executive Director | no data | HK$14.79m | 0.023% HK$ 776.2k | |
| President & Executive Director | no data | HK$2.58m | 0.065% HK$ 2.1m | |
| Senior VP | no data | HK$1.60m | 0.023% HK$ 776.2k | |
| VP, Chief Scientific Officer & Executive Director | 5.4yrs | HK$6.13m | no data | |
| Independent Non-Executive Director | 21.8yrs | HK$100.00k | 0.0021% HK$ 69.0k | |
| Co-Chairman of Vitaquest International LLC | no data | no data | no data | |
| Non-Executive Director | 22yrs | HK$75.00k | 0.011% HK$ 362.1k | |
| Independent Non-executive Director | 9.1yrs | HK$155.00k | no data | |
| Independent Non-Executive Director | 3.8yrs | HK$205.00k | no data | |
| Independent Non-Executive Director | 4.8yrs | HK$205.00k | no data |
9.1yrs
Average Tenure
71yo
Average Age
Experienced Board: 775's board of directors are considered experienced (9.1 years average tenure).